10-Q: Monogram Technologies Reports Q3 2024 Results, Provides Update on FDA Filing and Capital Raises

Monogram Technologies reported a net loss of $5.03 million for the third quarter of 2024, while also providing updates on their FDA 510(k) submission and recent capital raising activities.

Summary

• Monogram Technologies, an AI-driven robotics company focused on orthopedic surgery, reported a net loss of $5.03 million for the three months ended September 30, 2024, and a net loss of $12.08 million for the nine months ended September 30, 2024.
• The company's operating expenses totaled $5.15 million for the quarter and $12.39 million for the nine-month period.
• Research and development expenses decreased by 17% in the third quarter and 7% in the nine-month period compared to 2023, due to the completion of the validation phase of their robot prototype.
• Marketing and advertising expenses increased significantly in the third quarter due to the Series D preferred stock offering, but decreased by 28% for the nine-month period compared to 2023.
• General and administrative expenses increased by 3% in the third quarter and 11% in the nine-month period, driven by higher insurance, regulatory compliance, and professional fees.
• Monogram submitted a 510(k) premarket filing to the FDA for its semi-active mBs TKA System in July 2024 and received an Additional Information Request (AIR) in September 2024.
• The company closed its Series D Preferred Stock offering on October 2, 2024, raising approximately $13 million in gross proceeds.
• Monogram also has an at-the-market common stock offering program, under which it has sold 1,592,023 shares for gross proceeds of $4.27 million as of November 12, 2024.
• As of September 30, 2024, the company had $16.6 million in cash on hand and total stockholders' equity of $17.4 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in its product development and capital raising efforts, the increasing losses and the FDA's request for additional information are concerning. The company's future success is highly dependent on obtaining regulatory approvals and generating revenue.

Positives

• Monogram successfully closed its Series D Preferred Stock offering, raising approximately $13 million in gross proceeds.
• The company has an active at-the-market common stock offering program, providing additional capital raising flexibility.
• Monogram has completed the validation phase of its robot prototype, leading to a decrease in research and development expenses.
• The company has submitted its 510(k) premarket filing to the FDA for its semi-active mBs TKA System.
• Monogram has $16.6 million in cash on hand as of September 30, 2024.

Negatives

• Monogram reported a net loss of $5.03 million for the third quarter of 2024, an 80% increase compared to the same period in 2023.
• The company's net loss for the nine months ended September 30, 2024, was $12.08 million, a 16% increase compared to the same period in 2023.
• The company has not yet generated any revenue from product sales.
• Monogram received an Additional Information Request (AIR) from the FDA regarding its 510(k) submission, which could delay the approval process.
• The company is in discussions with Mount Sinai regarding a potential payment obligation related to a licensing agreement, which could have a material adverse effect on operations.

Risks

• The company's ability to continue as a going concern is dependent on its ability to generate revenue, raise capital, and obtain financing.
• The FDA approval process for the company's robotic products is uncertain, and delays could impact the company's commercialization timeline.
• The company is in discussions with Mount Sinai regarding a potential payment obligation related to a licensing agreement, which could have a material adverse effect on operations.
• The company has incurred significant losses since inception and has an accumulated deficit of $63.7 million as of September 30, 2024.
• The company may need to raise additional capital through equity or debt financings, which could dilute existing shareholders or impose restrictive covenants.

Future Outlook

The company believes its current cash balances, plus additional capital available under the Common Stock Purchase Agreement and At the Market Common Stock Offering, will be sufficient to satisfy near-term capital needs and continue as a going concern for a reasonable period. The company anticipates holding an issue-specific meeting with the FDA by December 2024, pending FDA availability.

Management Comments

• Management believes the patent landscape for haptic control and the widespread adoption of products like Mako could be favorable for next-generation active cutting robots like Monogram's mBs TKA System.
• Management found the teleconference with the FDA to address the clarification questions in the AIR to be constructive.
• Management believes its current cash balances, plus the additional capital available under the Common Stock Purchase Agreement and At The Market Common Stock Offerings will be sufficient for the Company to satisfy its near-term capital needs and to continue as a going concern for a reasonable period.

Industry Context

The company is operating in the growing market of robotic surgery, specifically targeting the orthopedic sector. The company believes its active cutting robotic system, which does not utilize haptic controls, has a significant market opportunity. The company is competing with established players in the market, such as Mako, which uses haptic control technology.

Comparison to Industry Standards

• Monogram is developing a robotic system for orthopedic surgery, a market where companies like Stryker (with Mako) and Zimmer Biomet are established players.
• Unlike Mako, Monogram's mBs TKA System is designed to efficiently resect bone without utilizing haptic controls, which the company believes is a competitive advantage.
• The company's focus on AI and advanced machine vision aligns with the broader trend of incorporating these technologies into medical devices.
• The company's financial results are typical of early-stage medical device companies that are still in the development and regulatory approval phase, with significant operating losses and reliance on capital raises.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may be impacted by the company's financial performance and ability to continue operations.
• Customers (surgeons and patients) are awaiting the commercialization of the company's robotic system.
• Suppliers and creditors are dependent on the company's ability to meet its financial obligations.

Next Steps

• The company will respond to the FDA's Additional Information Request (AIR) for its 510(k) submission.
• The company anticipates holding an issue-specific meeting with the FDA by December 2024.
• The company will continue to sell shares of common stock through its at-the-market offering program.
• The company will continue to explore additional financing options to support its operations.

Key Dates

Keywords

robotics, orthopedic surgery, FDA 510(k), capital raise, preferred stock, common stock, mBs TKA System, AI, medical devices, implants